A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS
about
New developments and future opportunities in biomarkers for amyotrophic lateral sclerosisALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.Use of biomarkers in ALS drug development and clinical trialsMetabolomics in amyotrophic lateral sclerosis: how far can it take us?Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.Further development of biomarkers in amyotrophic lateral sclerosis.Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis.Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis.Biomarkers in Neurodegenerative Diseases.Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis.Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement.Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease.Neuronal apoptosis inhibitory protein is implicated in amyotrophic lateral sclerosis symptoms.Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials.A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression.
P2860
Q26783410-C4735528-52BA-4720-ACA6-FBEA075BA89FQ34554820-BB5A1D10-C2C5-4EBD-80AA-4C9AF59A8B5EQ36177001-B291A1A6-A619-4964-8ED3-B245DA435802Q36733981-73EC20E4-8533-415A-821D-1DBC3104487EQ38715322-A983E541-CA4B-4760-894F-E318A7C784EBQ38847200-8BBD859C-727D-4969-A695-1610094C6C8AQ38856405-0377242A-6097-478B-B8B1-144B172D26B4Q38994757-4F9C2DD5-356A-4564-94C2-E0E81BF49308Q39033841-8892A9ED-B17C-4A6A-8086-21C74CAA9A8EQ39413097-C5A8F7D5-BC91-4B6F-AFC9-AE2116F754E2Q41024423-F8611CA0-5E45-44DE-BFC6-6F17A94E15D8Q42369773-721FC332-E66D-4A4F-9F78-AE611F06771CQ45023714-50914B2B-3865-4763-B460-98E6A2D5D001Q47222540-29E68C60-9804-4443-976A-3A4C576B0B71Q47688852-C72E3AC6-FE0F-4F1B-BECD-6DA2B54B23B8Q55246233-7676E207-C634-4BEA-9465-FDBCC72F74F2
P2860
A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2014
@uk
name
A post hoc analysis of subgrou ...... OWER) of dexpramipexole in ALS
@en
A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial
@nl
type
label
A post hoc analysis of subgrou ...... OWER) of dexpramipexole in ALS
@en
A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial
@nl
prefLabel
A post hoc analysis of subgrou ...... OWER) of dexpramipexole in ALS
@en
A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial
@nl
P2093
P2860
P50
P1476
A post hoc analysis of subgrou ...... OWER) of dexpramipexole in ALS
@en
P2093
Benjamin R. Brooks
Bing Zhang
Dan H. Moore
Donald Archibald
James Mather
Michael E. Bozik
Stacy A. Rudnicki
Thomas Petzinger
P2860
P304
P356
10.3109/21678421.2014.943672
P577
2014-08-15T00:00:00Z